CRYSTALLINE FORM OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1 H-PYRAZOL-3-YLAMINO)-6-ETHYL-1 -METHYL-1,6-DIHYDROIMIDAZO[4,5- D]FY RROLO[2,3-B]PYRIDINE-7-CARBOXAMIDE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS
Crystalline form, Form T2H1.5-4, of N,Ndicyclopropyl-4- (1,5-dimethyl-l Hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6- dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (Compound (I)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising Form T2H1.5-4 of Compound (I) as well as a method of using the Form T2H1.5-4 of Compound (I) in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.Linvention concerne une forme cristalline, la forme T2H1.5-4, de N,N-dicyclopropyle-4-(1,5-diméthyl-1H-pyrazol-3-ylamino)-6-éthyl-1-méthyl-1,6-dihydro-imidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide (Composé I). Linvention concerne également une composition pharmaceutique et une forme posologique orale comprenant la forme T2H1.5-4 du composé I, ainsi quune méthode dutilisation de la forme T2H1.5-4 du composé I dans le traitement de troubles myéloprolifératifs, qui comprennent la polyglobulie primitive, la thrombocytémie et la myélofibrose primaire.
